Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Regenerex Pharma, Inc.
regenerexprh.comAI Executive Summary
AI-powered analysis of 8-K filing content
Regenerex Pharma's Board placed CFO Kenneth Perry on administrative leave with pay effective March 31, 2026, citing concerns over compliance, financial oversight, and corporate governance. This executive departure signals potential internal control issues that could impact investor confidence and financial reporting reliability.
Key Takeaways
CFO Kenneth Perry was placed on administrative suspension with pay, indicating a significant governance concern rather than a voluntary departure
The Board reassigned Perry's responsibilities to an interim CFO, suggesting the company is maintaining continuity while investigating underlying issues
2 more takeaways